Gaia Trade Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Gaia Trade Private Limited Pharmaceutical Export Portfolio Dataset — 3 Products, $503.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Gaia Trade Private Limited — Pharmaceutical Exporter Profile (2026) | 3 Products, $503.6K Trade | TransData Nexus

Gaia Trade Private Limited

Indian Pharmaceutical Exporter · Advanced Diabetes Medications Specialist · $503.6K Total Trade · DGFT Verified

Gaia Trade Private Limited is an Indian pharmaceutical exporter with a total trade value of $503.6K across 3 products in 2 therapeutic categories. Based on 623 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Semaglutide ($350.1K), Empagliflozin ($151.4K), Canagliflozin ($2.2K).

Gaia Trade Private Limited — Export Portfolio & Destination Treemap

Gaia Trade Private Limited pharmaceutical export portfolio — 3 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Gaia Trade Private Limited? — Company Overview & Market Position

Gaia Trade Private Limited, established on 14 September 2012, is a private limited company based in Dabolim, Goa, India. The company is registered under the Corporate Identification Number (CIN) U51900GA2012PTC007044. Its authorized capital is ₹500,000, with a paid-up capital of ₹197,110. The registered office is located at Shop No.14, Ground Floor, Survey No.8/1, Umiya Quatro D, Commercia, Dabolim, Goa, 403801.

Gaia Trade Private Limited specializes in the wholesale and export of pharmaceutical products, focusing on finished pharmaceutical formulations such as tablets, capsules, syrups, and injections. The company operates under strict compliance with international regulatory frameworks, including the EU Good Distribution Practice (GDP) standards, ensuring the quality and safety of its products.

What Does Gaia Trade Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Semaglutide$350.1K 2Empagliflozin

Product Portfolio — Top 3 by Export Value

Gaia Trade Private Limited exports 3 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Semaglutide	Advanced Diabetes Medications	$350.1K	250	7.0%	4
2	Empagliflozin	Diabetes & Endocrine	$151.4K	350	2.3%	11
3	Canagliflozin	Advanced Diabetes Medications	$2.2K	23	0.2%	14

Gaia Trade Private Limited exports 3 pharmaceutical products across 2 therapeutic categories with a total export value of $503.6K. The top category is Advanced Diabetes Medications (69.9% of portfolio), followed by Diabetes & Endocrine (30.1%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Gaia Trade Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Gaia Trade Private Limited does not own manufacturing facilities; instead, it sources pharmaceutical products from manufacturers and authorized distributors. The company emphasizes compliance with international standards, including EU GDP, to ensure the quality and safety of its products.

3Key Leadership

The leadership team of Gaia Trade Private Limited comprises:

Eran Niv: Managing Director since 14 September 2012.
Ritu Sikka: Managing Director since 14 September 2012.
Sanjay Balkrishna Salgaonker: Director since 28 December 2017.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Gaia Trade Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Gaia Trade Private Limited's export activities are primarily focused on finished pharmaceutical formulations, including advanced diabetes medications such as Semaglutide, Empagliflozin, and Canagliflozin. The company's total export value is $504,000 USD, with 623 shipments across 3 products in 2 therapeutic categories. The top three products are:

Semaglutide: $350,000 USD, Rank #4, 7.0% market share.
Empagliflozin: $151,000 USD, Rank #11, 2.3% market share.
Canagliflozin: $2,000 USD, Rank #14, 0.2% market share.

The primary therapeutic categories are Advanced Diabetes Medications (69.9%) and Diabetes & Endocrine (30.1%). The company's portfolio is highly concentrated, with the top three products accounting for 100% of the export value.

2Emerging Markets

Gaia Trade Private Limited has a global reach, serving over 50 countries across multiple continents. The company specializes in providing high-quality, cost-effective medications sourced from India, catering to a diverse clientele that includes pharmacies, hospitals, clinics, NGOs, and insurers. By sourcing products from WHO-GMP, US FDA, and EU-GMP certified manufacturers, Gaia Trade ensures authenticity and adherence to international safety standards.

Gaia Trade Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As of the latest available data, Gaia Trade Private Limited does not have FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), or Drug Master File (DMF) filings. The company primarily focuses on sourcing and exporting finished pharmaceutical formulations rather than manufacturing. Consequently, it does not have an FDA inspection history.

2WHO & EU GMP

Gaia Trade Private Limited sources its pharmaceutical products from manufacturers and authorized distributors that are certified by the World Health Organization's Good Manufacturing Practice (WHO-GMP) and the European Union's Good Manufacturing Practice (EU GMP). This ensures that the products meet international quality and safety standards.

3CDSCO & Indian Regulatory

Gaia Trade Private Limited operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds the necessary licenses and approvals to engage in the wholesale and export of pharmaceutical products. Specific details regarding manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed.

Gaia Trade Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Gaia Trade Private Limited operates in a competitive pharmaceutical export market, focusing on finished pharmaceutical formulations in the diabetes and endocrine therapeutic categories. While specific competitors are not identified in the available data, the company's emphasis on compliance with international standards, such as EU GDP, and its sourcing from WHO-GMP, US FDA, and EU-GMP certified manufacturers position it favorably in the market. However, the high concentration of its product portfolio may limit its competitiveness in other therapeutic areas.

2Key Differentiators

Gaia Trade Private Limited's key differentiators include its strict adherence to international regulatory frameworks, such as EU GDP, and its sourcing of products from certified manufacturers. The company's ability to handle flexible order quantities, from single vials to full pallets, and its specialization in serving small-to-medium organizations, including NGOs and humanitarian groups, further distinguish it in the market.

3Strategic Position

Gaia Trade Private Limited's current strategic direction focuses on the wholesale and export of finished pharmaceutical formulations, particularly in the diabetes and endocrine therapeutic categories. The company's emphasis on compliance and quality positions it as a reliable partner in global pharmaceutical trade. Future strategic initiatives may include diversifying the product portfolio to mitigate concentration risks and exploring new therapeutic areas to expand market reach.

Buyer Due Diligence Brief — Evaluating Gaia Trade Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Gaia Trade Private Limited demonstrates a strong track record in sourcing and exporting pharmaceutical products, with a total export value of $504,000 USD and 623 shipments across 3 products. The company's commitment to compliance with international standards and its sourcing from certified manufacturers indicate reliability and consistency in its operations. However, the high concentration of its product portfolio suggests a need for diversification to enhance long-term sustainability.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and compliance:

FDA Approval: Confirm that the product is approved by the U.S. Food and Drug Administration.
WHO-GMP Certification: Ensure the manufacturer holds a valid WHO-GMP certificate.
EU GMP Certification: Verify the manufacturer's EU GMP certification.

Frequently Asked Questions — Gaia Trade Private Limited

How many pharmaceutical products does Gaia Trade Private Limited export from India?

Gaia Trade Private Limited exports 3 pharmaceutical products across 2 therapeutic categories. The top exports are Semaglutide ($350.1K), Empagliflozin ($151.4K), Canagliflozin ($2.2K). Total export value is $503.6K.

What is Gaia Trade Private Limited's total pharmaceutical export value?

Gaia Trade Private Limited's total pharmaceutical export value is $503.6K, based on 623 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Gaia Trade Private Limited cover?

Gaia Trade Private Limited exports across 2 therapeutic categories. The largest are Advanced Diabetes Medications (69.9%, 2 products), Diabetes & Endocrine (30.1%, 1 products).

Get Full Gaia Trade Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.